A federal appeals court granted Illumina Inc.'s request for a faster review of its suit challenging the Federal Trade Commission’s order to unwind its $7 billion acquisition of cancer start-up Grail.
The US Court of Appeals for the Fifth Circuit set aside the FTC’s objections as it agreed Tuesday to speedily take up review of the case. Judge James Graves, one of the three judges on a panel that issued the ruling, noted he would have denied the motion.
Illumina spun off Grail in 2016 to develop a blood test to detect early stages of cancer. Illumina moved to buy ...